Search
Palladium Pd-103
go.drugbank.com/drugs/DB15016ExperimentalPalladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Zimlovisertib
go.drugbank.com/drugs/DB15143InvestigationalPF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
PF-06821497
go.drugbank.com/drugs/DB14799InvestigationalPF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).
PF-05089771
go.drugbank.com/drugs/DB14856InvestigationalPF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).
PF-05180999
go.drugbank.com/drugs/DB14885InvestigationalPF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).
PF-04937319
go.drugbank.com/drugs/DB15009InvestigationalPF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
PF-06291874
go.drugbank.com/drugs/DB15065InvestigationalPF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes
PF-06882961
go.drugbank.com/drugs/DB16043InvestigationalPF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
Sucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalIt is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Products: SUCRALFATO MYLAN GENERICS, SUCRALFATO DOC GENERICIBuspirone
go.drugbank.com/drugs/DB00490ApprovedInvestigational[A180985] First synthesized in 1968 then patented in 1975,[L7375] it is commonly marketed under the brand name Buspar®.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates